Overview

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

Status:
Completed

Trial end date:
2017-02-14

Target enrollment:

Participant gender:

Summary

This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Cinacalcet Hydrochloride